## Mario Tumbarello

# List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/6950505/mario-tumbarello-publications-by-year.pdf

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

164<br/>papers8,333<br/>citations50<br/>h-index87<br/>g-index173<br/>ext. papers9,892<br/>ext. citations6.7<br/>avg, IF5.5<br/>L-index

#	Paper	IF	Citations
164	Risk Factors for Intra-Abdominal Candidiasis in Intensive Care Units: Results from EUCANDICU Study <i>Infectious Diseases and Therapy</i> , <b>2022</b> , 11, 827-840	6.2	O
163	Compassionate use of meropenem/vaborbactam for infections caused by KPC-producing: a multicentre study <i>JAC-Antimicrobial Resistance</i> , <b>2022</b> , 4, dlac022	2.9	3
162	New Drugs for the Treatment of Pseudomonas aeruginosa Infections with Limited Treatment Options: A Narrative Review. <i>Antibiotics</i> , <b>2022</b> , 11, 579	4.9	3
161	Epidemiology, aetiology and treatment of skin and soft tissue infections: final report of a prospective multicentre national registry <i>Journal of Chemotherapy</i> , <b>2022</b> , 1-10	2.3	О
160	European Society of clinical microbiology and infectious diseases (ESCMID) guidelines for the treatment of infections caused by Multidrug-resistant Gram-negative bacilli (endorsed by ESICM -European Society of intensive care Medicine) Clinical Microbiology and Infection, 2021,	9.5	27
159	A new call for influenza and pneumococcal vaccinations during COVID-19 pandemic in Italy: A SIP/IRS (Italian Respiratory Society) and SITA (Italian Society of Antiinfective therapy) statement. <i>Respiratory Medicine</i> , <b>2021</b> , 190, 106674	4.6	1
158	Staphylococcus aureus ventilator-associated pneumonia in patients with COVID-19: clinical features and potential inference with lung dysbiosis. <i>Critical Care</i> , <b>2021</b> , 25, 197	10.8	16
157	Efficacy of Elactam/Elactamase inhibitors to treat extended-spectrum beta-lactamase-producing Enterobacterales bacteremia secondary to urinary tract infection in kidney transplant recipients (INCREMENT-SOT Project). <i>Transplant Infectious Disease</i> , <b>2021</b> , 23, e13520	2.7	1
156	Considerations on antimicrobial prophylaxis in patients with lymphoproliferative diseases: A SEIFEM group position paper. <i>Critical Reviews in Oncology/Hematology</i> , <b>2021</b> , 158, 103203	7	1
155	Ceftazidime-Avibactam Use for Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae Infections: A Retrospective Observational Multicenter Study. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 73, 1664	-1676	32
154	Characterisation and risk factor profiling of Pseudomonas aeruginosa urinary tract infections: pinpointing those likely to be caused by multidrug-resistant strains. <i>International Journal of Antimicrobial Agents</i> , <b>2020</b> , 55, 105900	14.3	5
153	Pharmacokinetics of high-dose tigecycline in critically ill patients with severe infections. <i>Annals of Intensive Care</i> , <b>2020</b> , 10, 94	8.9	15
152	Evaluating Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacilli: A Review of the Emerging Data. <i>Infection and Drug Resistance</i> , <b>2020</b> , 13, 4697-4711	4.2	12
151	Molecular Mechanisms, Epidemiology, and Clinical Importance of Lactam Resistance in. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	15
150	Risk Factors for Candidemia After Open Heart Surgery: Results From a Multicenter Case-Control Study. <i>Open Forum Infectious Diseases</i> , <b>2020</b> , 7, ofaa233	1	2
149	(1,3)-ED-Glucan-based empirical antifungal interruption in suspected invasive candidiasis: a randomized trial. <i>Critical Care</i> , <b>2020</b> , 24, 550	10.8	7
148	Use of colistin in adult patients: A cross-sectional study. <i>Journal of Global Antimicrobial Resistance</i> , <b>2020</b> , 20, 43-49	3.4	16

147	Meropenem/vaborbactam: a next generation Elactam Elactamase inhibitor combination. <i>Expert Review of Anti-Infective Therapy</i> , <b>2020</b> , 18, 643-655	5.5	28
146	Ceftolozane/Tazobactam for Treatment of Severe ESBL-Producing Infections: A Multicenter Nationwide Clinical Experience (CEFTABUSE II Study). <i>Open Forum Infectious Diseases</i> , <b>2020</b> , 7, ofaa139	1	24
145	Bloodstream infections caused by Escherichia coli in onco-haematological patients: Risk factors and mortality in an Italian prospective survey. <i>PLoS ONE</i> , <b>2019</b> , 14, e0224465	3.7	14
144	Bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii: Clinical features, therapy and outcome from a multicenter study. <i>Journal of Infection</i> , <b>2019</b> , 79, 130-138	18.9	31
143	Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: results of the EUCANDICU project. <i>Critical Care</i> , <b>2019</b> , 23, 219	10.8	64
142	Direct use of eazyplex SuperBug CRE assay from positive blood cultures in conjunction with inpatient infectious disease consulting for timely appropriate antimicrobial therapy in and bloodstream infections. <i>Infection and Drug Resistance</i> , <b>2019</b> , 12, 1055-1062	4.2	7
141	Fungaemia in haematological malignancies: SEIFEM-2015 survey. <i>European Journal of Clinical Investigation</i> , <b>2019</b> , 49, e13083	4.6	10
140	Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by Klebsiella pneumoniae Carbapenemase-producing K. pneumoniae. <i>Clinical Infectious Diseases</i> , <b>2019</b> , 68, 355-364	11.6	163
139	Predictors of mortality in solid organ transplant recipients with bloodstream infections due to carbapenemase-producing Enterobacterales: The impact of cytomegalovirus disease and lymphopenia. <i>American Journal of Transplantation</i> , <b>2019</b> , 20, 1629	8.7	7
138	The role of carbapenem-resistant pathogens in cSSTI and how to manage them. <i>Current Opinion in Infectious Diseases</i> , <b>2019</b> , 32, 113-122	5.4	9
137	Risk factors for mortality and cost implications of complicated intra-abdominal infections in critically ill patients. <i>Journal of Critical Care</i> , <b>2019</b> , 50, 169-176	4	13
136	Ceftolozane/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience. <i>International Journal of Antimicrobial Agents</i> , <b>2019</b> , 53, 408-4	4 <mark>14</mark> .3	80
135	'Real-life' analysis of the role of antifungal prophylaxis in preventing invasive aspergillosis in AML patients undergoing consolidation therapy: Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) 2016 study. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2019</b> , 74, 1062-1068	5.1	5
134	Desirability of outcome ranking (DOOR) for comparing diagnostic tools and early therapeutic choices in patients with suspected candidemia. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , <b>2019</b> , 38, 413-417	5.3	9
133	Epidemiology and Microbiology of Skin and Soft Tissue Infections: Preliminary Results of a National Registry. <i>Journal of Chemotherapy</i> , <b>2019</b> , 31, 9-14	2.3	11
132	Ceftolozane/tazobactam: place in therapy. Expert Review of Anti-Infective Therapy, 2018, 16, 307-320	5.5	65
131	Predictors of Mortality with Staphylococcus aureus Bacteremia in Elderly Adults. <i>Journal of the American Geriatrics Society</i> , <b>2018</b> , 66, 1284-1289	5.6	9
130	The current role of glycopeptides in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in not neutropenic adults: the viewpoint of a group of Italian experts. <i>Journal of Chemotherapy</i> , <b>2018</b> , 30, 157-171	2.3	

129	Febrile events in acute lymphoblastic leukemia: a prospective observational multicentric SEIFEM study (SEIFEM-2012/B ALL). <i>Annals of Hematology</i> , <b>2018</b> , 97, 791-798	3	6
128	Effect of combination therapy containing a high-dose carbapenem on mortality in patients with carbapenem-resistant Klebsiella pneumoniae bloodstream infection. <i>International Journal of Antimicrobial Agents</i> , <b>2018</b> , 51, 244-248	14.3	42
127	Optimizing therapy in carbapenem-resistant Enterobacteriaceae infections. <i>Current Opinion in Infectious Diseases</i> , <b>2018</b> , 31, 566-577	5.4	31
126	T2Bacteria magnetic resonance assay for the rapid detection of ESKAPEc pathogens directly in whole blood. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2018</b> , 73, iv20-iv26	5.1	45
125	Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extended-spectrum-flactamase-producing Enterobacteriaceae. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2017</b> , 72, 906-913	5.1	36
124	Therapeutic options for carbapenem-resistant Enterobacteriaceae infections. Virulence, 2017, 8, 470-48	8 <b>4</b> 4.7	74
123	Clinical characteristics and predictors of mortality in cirrhotic patients with candidemia and intra-abdominal candidiasis: a multicenter study. <i>Intensive Care Medicine</i> , <b>2017</b> , 43, 509-518	14.5	37
122	Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. <i>Lancet Infectious Diseases, The</i> , <b>2017</b> , 17, 726-734	25.5	268
121	SEIFEM 2010-E: economic evaluation of posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia receiving induction chemotherapy. <i>Leukemia and Lymphoma</i> , <b>2017</b> , 58, 2859-28	36 <sup>1</sup> 4 <sup>9</sup>	4
120	Prosthetic valve endocarditis: predictors of early outcome of surgical therapy. A multicentric study. <i>European Journal of Cardio-thoracic Surgery</i> , <b>2017</b> , 52, 768-774	3	16
119	Invasive Candida Infections in Liver Transplant Recipients: Clinical Features and Risk Factors for Mortality. <i>Transplantation Direct</i> , <b>2017</b> , 3, e156	2.3	27
118	Diagnosis and management of skin and soft-tissue infections (SSTI). A literature review and consensus statement: an update. <i>Journal of Chemotherapy</i> , <b>2017</b> , 29, 197-214	2.3	54
117	The defining a model for antimicrobial stewardship-results from an international cross-sectional survey. <i>World Journal of Emergency Surgery</i> , <b>2017</b> , 12, 34	9.2	35
116	Combined use of serum (1,3)-ED-glucan and procalcitonin for the early differential diagnosis between candidaemia and bacteraemia in intensive care units. <i>Critical Care</i> , <b>2017</b> , 21, 176	10.8	42
115	Changes in the incidence of candidemia and related mortality in patients with hematologic malignancies in the last ten years. A SEIFEM 2015-B report. <i>Haematologica</i> , <b>2017</b> , 102, e407-e410	6.6	15
114	Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study. <i>International Journal of Antimicrobial Agents</i> , <b>2017</b> , 50, 664-672	14.3	8
113	A Global Declaration on Appropriate Use of Antimicrobial Agents across the Surgical Pathway. <i>Surgical Infections</i> , <b>2017</b> , 18, 846-853	2	21
112	Antibodies against a Eglucan-protein complex of Candida albicans and its potential as indicator of protective immunity in candidemic patients. <i>Scientific Reports</i> , <b>2017</b> , 7, 2722	4.9	9

### (2015-2017)

111	Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations. <i>Blood Reviews</i> , <b>2017</b> , 31, 17-29	11.1	70
110	Empiric Therapy With Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum Lactamase-Producing Enterobacteriaceae: Results From the INCREMENT Cohort. Clinical Infectious Diseases, 2017, 65, 1615-1623	11.6	33
109	Carbapenem-Resistant Infections: Results From a Retrospective Series and Implications for the Design of Prospective Clinical Trials. <i>Open Forum Infectious Diseases</i> , <b>2017</b> , 4, ofx063	1	38
108	Characteristics of Staphylococcus aureus Bacteraemia and Predictors of Early and Late Mortality. <i>PLoS ONE</i> , <b>2017</b> , 12, e0170236	3.7	38
107	Bloodstream infections caused by Klebsiella pneumoniae in onco-hematological patients: clinical impact of carbapenem resistance in a multicentre prospective survey. <i>American Journal of Hematology</i> , <b>2016</b> , 91, 1076-1081	7.1	78
106	Is first-line antimicrobial therapy still adequate to treat MRSA in the ICU? A report from a highly endemic country. <i>Critical Care</i> , <b>2016</b> , 20, 246	10.8	7
105	Comment on: Mortality due to blaKPC Klebsiella pneumoniae bacteraemia. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2016</b> , 71, 1743-4	5.1	5
104	Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2016</b> , 71, 1672-80	5.1	33
103	Bloodstream Infections in Hematological Cancer Patients Colonized By Multiresistant Bacteria: Final Results of a Multicentric Prospective Observational Seifem Study. <i>Blood</i> , <b>2016</b> , 128, 3700-3700	2.2	
102	(1,3)-Ed-Glucan-based antifungal treatment in critically ill adults at high risk of candidaemia: an observational study. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2016</b> , 71, 2262-9	5.1	49
101	A Multinational, Preregistered Cohort Study of £Lactam/£Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-£Lactamase-Producing Enterobacteriaceae. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2016</b> , 60, 4159-69	5.9	96
100	A Predictive Model of Mortality in Patients With Bloodstream Infections due to Carbapenemase-Producing Enterobacteriaceae. <i>Mayo Clinic Proceedings</i> , <b>2016</b> , 91, 1362-1371	6.4	66
99	MEDical wards Invasive Candidiasis ALgorithms (MEDICAL):Consensus proposal for management. <i>European Journal of Internal Medicine</i> , <b>2016</b> , 34, 45-53	3.9	6
98	A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality. <i>Intensive Care Medicine</i> , <b>2015</b> , 41, 1601-10	14.5	125
97	Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2015</b> , 70, 2133-43	5.1	334
96	Antifungal susceptibility profiles of bloodstream yeast isolates by Sensititre YeastOne over nine years at a large Italian teaching hospital. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2015</b> , 59, 3944-55	5.9	58
95	Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria. <i>Intensive Care Medicine</i> , <b>2015</b> , 41, 776-95	14.5	105
94	Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre studyauthors' response. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2015</b> , 70, 2922	5.1	45

93	Reply to Wong et al. <i>Clinical Infectious Diseases</i> , <b>2015</b> , 61, 1352	11.6	1
92	Multidrug-resistant bacteria and bloodstream infections in onco-hematological patients. <i>Journal of Chemotherapy</i> , <b>2015</b> , 27, 250-2	2.3	1
91	Risk of invasive fungal infection in patients affected by acute promyelocytic leukaemia. A report by the SEIFEM-D registry. <i>British Journal of Haematology</i> , <b>2015</b> , 170, 434-9	4.5	13
90	Fungal infections in the ICU: advances in treatment and diagnosis. <i>Current Opinion in Critical Care</i> , <b>2015</b> , 21, 421-9	3.5	23
89	Pre-chemotherapy risk factors for invasive fungal diseases: prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010-a multicenter study). <i>Haematologica</i> , <b>2015</b> , 100, 284-92	6.6	50
88	Linezolid plasma and intrapulmonary concentrations in critically ill obese patients with ventilator-associated pneumonia: intermittent vs continuous administration. <i>Intensive Care Medicine</i> , <b>2015</b> , 41, 103-10	14.5	24
87	Bloodstream Infections Caused By Klebsiella Pneumoniae in Onco-Hematological Patients: Incidence and Clinical Impact of Carbapenem Resistance in a Multicentre Prospective Survey. <i>Blood</i> , <b>2015</b> , 126, 3757-3757	2.2	2
86	Bloodstream Infections in Hematological Cancer Patients Colonized By Multiresistant Bacteria: Results of a Multicentric Prospective Observational Seifem Study. <i>Blood</i> , <b>2015</b> , 126, 1023-1023	2.2	
85	Epidemiology of Fungemia in Hematological Malignancies: Preliminary Report of Seifem-2015 Survey. <i>Blood</i> , <b>2015</b> , 126, 4887-4887	2.2	
84	Clinical experience of colistin-glycopeptide combination in critically ill patients infected with Gram-negative bacteria. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2014</b> , 58, 851-8	5.9	80
83	Predictive models for identification of hospitalized patients harboring KPC-producing Klebsiella pneumoniae. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2014</b> , 58, 3514-20	5.9	62
82	High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria. <i>Critical Care</i> , <b>2014</b> , 18, R90	10.8	149
81	Performance of two resin-containing blood culture media in detection of bloodstream infections and in direct matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) broth assays for isolate identification: clinical comparison of the BacT/Alert Plus	9.7	33
80	and Bactec Plus systems. <i>Journal of Clinical Microbiology</i> , <b>2014</b> , 52, 3558-67 Systemic antifungal treatment after posaconazole prophylaxis: results from the SEIFEM 2010-C survey. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2014</b> , 69, 3142-7	5.1	15
79	A multicenter study of septic shock due to candidemia: outcomes and predictors of mortality. <i>Intensive Care Medicine</i> , <b>2014</b> , 40, 839-45	14.5	173
78	Response. <i>Chest</i> , <b>2014</b> , 145, 927	5.3	
77	Carbapenemase-producing Klebsiella pneumoniae and hematologic malignancies. <i>Emerging Infectious Diseases</i> , <b>2014</b> , 20, 1235-6	10.2	37
76	Antimicrobial-resistant Gram-negative bacteria in febrile neutropenic patients with cancer: current epidemiology and clinical impact. <i>Current Opinion in Infectious Diseases</i> , <b>2014</b> , 27, 200-10	5.4	81

75	Relapsing bloodstream infections during treatment of acute leukemia. <i>Annals of Hematology</i> , <b>2014</b> , 93, 785-90	3	13
74	Carbapenem-Resistant Enterobacteriaceae (CRE) and Their Impact on Stem Cell Transplantation: A Single Center Experience. <i>Blood</i> , <b>2014</b> , 124, 3880-3880	2.2	1
73	Invasive Fungal Infections in Acute Promyelocytic Leukemia Patients. Results of a Prospective Multicenter Study in Italy. <i>Blood</i> , <b>2014</b> , 124, 3682-3682	2.2	
72	Epidemiology, species distribution, antifungal susceptibility, and outcome of candidemia across five sites in Italy and Spain. <i>Journal of Clinical Microbiology</i> , <b>2013</b> , 51, 4167-72	9.7	153
71	A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts. <i>Intensive Care Medicine</i> , <b>2013</b> , 39, 2092-106	14.5	138
70	Predictors of mortality in multidrug-resistant Klebsiella pneumoniae bloodstream infections. <i>Expert Review of Anti-Infective Therapy</i> , <b>2013</b> , 11, 1053-63	5.5	65
69	Clinical outcomes of Pseudomonas aeruginosa pneumonia in intensive care unit patients. <i>Intensive Care Medicine</i> , <b>2013</b> , 39, 682-92	14.5	101
68	Effect of aerosolized colistin as adjunctive treatment on the outcomes of microbiologically documented ventilator-associated pneumonia caused by colistin-only susceptible gram-negative bacteria. <i>Chest</i> , <b>2013</b> , 144, 1768-1775	5.3	114
67	Mortality in patients with early- or late-onset candidaemia. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2013</b> , 68, 927-35	5.1	34
66	Why should we monitor (1-3)-ED-glucan levels during invasive candidiasis? Just ask your ophthalmologist!. <i>Journal of Clinical Microbiology</i> , <b>2013</b> , 51, 1645-6	9.7	6
65	Safety and effectiveness of transvenous lead extraction in octogenarians. <i>Journal of Cardiovascular Electrophysiology</i> , <b>2012</b> , 23, 1103-8	2.7	16
64	Neurological involvement during legionellosis, look beyond the lung. <i>Journal of Neurology</i> , <b>2012</b> , 259, 2243-5	5.5	2
63	Direct maldi-tof mass spectrometry assay of blood culture broths for rapid identification of Candida species causing bloodstream infections: an observational study in two large microbiology laboratories. <i>Journal of Clinical Microbiology</i> , <b>2012</b> , 50, 176-9	9.7	155
62	Detecting risk and predicting patient mortality in patients with extended-spectrum Elactamase-producing Enterobacteriaceae bloodstream infections. <i>Future Microbiology</i> , <b>2012</b> , 7, 1173-89	<b>)</b> 2.9	45
61	Multidrug-resistant Proteus mirabilis bloodstream infections: risk factors and outcomes. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2012</b> , 56, 3224-31	5.9	34
60	Evaluation of the practice of antifungal prophylaxis use in patients with newly diagnosed acute myeloid leukemia: results from the SEIFEM 2010-B registry. <i>Clinical Infectious Diseases</i> , <b>2012</b> , 55, 1515-2	1 <sup>1.6</sup>	64
59	Risk factors and outcomes of candidemia caused by biofilm-forming isolates in a tertiary care hospital. <i>PLoS ONE</i> , <b>2012</b> , 7, e33705	3.7	146
58	Evaluation of the New NucliSENS EasyQ KPC test for rapid detection of Klebsiella pneumoniae carbapenemase genes (blaKPC). <i>Journal of Clinical Microbiology</i> , <b>2012</b> , 50, 2783-5	9.7	34

57	Reply to Identifying Patients Harboring Extended-Spectrum-Lactamase-Producing Enterobacteriaceae on Hospital Admission Is Not That Simple (International Agents and Chemotherapy, 2012, 56, 2220-2220)	5.9	78
56	Severe pneumonia in intensive care: cause, diagnosis, treatment and management: a review of the literature. <i>Current Opinion in Pulmonary Medicine</i> , <b>2012</b> , 18, 213-21	3	23
55	High-dose daptomycin for cardiac implantable electronic device-related infective endocarditis caused by staphylococcal small-colony variants. <i>Clinical Infectious Diseases</i> , <b>2012</b> , 54, 1516-7	11.6	10
54	Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. <i>Clinical Infectious Diseases</i> , <b>2012</b> , 55, 943-50	11.6	705
53	Derivation and validation of a scoring system to identify patients with bacteremia and hematological malignancies at higher risk for mortality. <i>PLoS ONE</i> , <b>2012</b> , 7, e51612	3.7	14
52	Uncommon yeast infections in hematological patients: from diagnosis to treatment. <i>Expert Review of Anti-Infective Therapy</i> , <b>2011</b> , 9, 1067-75	5.5	15
51	The use and efficacy of empirical versus pre-emptive therapy in the management of fungal infections: the HEMA e-Chart Project. <i>Haematologica</i> , <b>2011</b> , 96, 1366-70	6.6	44
50	Early diagnosis of candidemia in intensive care unit patients with sepsis: a prospective comparison of (1-a)-D-glucan assay, Candida score, and colonization index. <i>Critical Care</i> , <b>2011</b> , 15, R249	10.8	129
49	Esthesioneuroblastoma in an HIV-1 Infected Patient: Case Report. Skull Base Reports, 2011, 1, 129-32		
48	Etiology of febrile episodes in patients with acute myeloid leukemia: results from the Hema e-Chart Registry. <i>Archives of Internal Medicine</i> , <b>2011</b> , 171, 1502-3		22
47	Multidrug resistant Pseudomonas aeruginosa bloodstream infection in adult patients with hematologic malignancies. <i>Haematologica</i> , <b>2011</b> , 96, e1-3; author reply e4	6.6	58
46	Identifying patients harboring extended-spectrum-beta-lactamase-producing Enterobacteriaceae on hospital admission: derivation and validation of a scoring system. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2011</b> , 55, 3485-90	5.9	117
45	In vitro activities of anidulafungin and other antifungal agents against biofilms formed by clinical isolates of different Candida and Aspergillus species. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2011</b> , 55, 3031-5	5.9	58
44	Costs of bloodstream infections caused by Escherichia coli and influence of extended-spectrum-beta-lactamase production and inadequate initial antibiotic therapy. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2010</b> , 54, 4085-91	5.9	144
43	Fluconazole use as an important risk factor in the emergence of fluconazole-resistant Candida glabrata fungemia. <i>Archives of Internal Medicine</i> , <b>2009</b> , 169, 1444-5; author reply 1445		3
42	Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies. <i>Journal of Infection</i> , <b>2009</b> , 58, 299-307	18.9	124
41	Factors associated with mortality in bacteremic patients with hematologic malignancies. <i>Diagnostic Microbiology and Infectious Disease</i> , <b>2009</b> , 64, 320-6	2.9	71
40	Bloodstream infections caused by extended-spectrum-beta-lactamase- producing Escherichia coli: risk factors for inadequate initial antimicrobial therapy. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2008</b> , 52, 3244-52	5.9	86

#### (2002-2008)

39	Fungaemia caused by Candida glabrata with reduced susceptibility to fluconazole due to altered gene expression: risk factors, antifungal treatment and outcome. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2008</b> , 62, 1379-85	5.1	46
38	Oral lichenoid lesions in HIV-HCV-coinfected subjects during antiviral therapy: 2 cases and review of the literature. <i>American Journal of Dermatopathology</i> , <b>2008</b> , 30, 466-71	0.9	12
37	Oral lesions in HIV and HCV co-infected individuals in HAART era. <i>Journal of Oral Pathology and Medicine</i> , <b>2008</b> , 37, 468-74	3.3	5
36	Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2007</b> , 51, 1987-94	5.9	320
35	Biofilm production by Candida species and inadequate antifungal therapy as predictors of mortality for patients with candidemia. <i>Journal of Clinical Microbiology</i> , <b>2007</b> , 45, 1843-50	9.7	251
34	Predictors of Mortality in Patients with Bloodstream Infections Caused by Extended-Spectrum-Lactamase-Producing Enterobacteriaceae: Importance of Inadequate Initial Antimicrobial Treatment. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2007</b> , 51, 3469-3469	5.9	3
33	Incidence, risk factors, and predictors of outcome of candidemia. Survey in 2 Italian university hospitals. <i>Diagnostic Microbiology and Infectious Disease</i> , <b>2007</b> , 58, 325-31	2.9	89
32	Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2006</b> , 50, 498-504	5.9	194
31	Evaluation of the new VITEK 2 extended-spectrum beta-lactamase (ESBL) test for rapid detection of ESBL production in Enterobacteriaceae isolates. <i>Journal of Clinical Microbiology</i> , <b>2006</b> , 44, 3257-62	9.7	37
30	Azole resistance of Candida glabrata in a case of recurrent fungemia. <i>Journal of Clinical Microbiology</i> , <b>2006</b> , 44, 3046-7	9.7	21
29	Candida infections in the intensive care unit: epidemiology, risk factors and therapeutic strategies. <i>Expert Review of Anti-Infective Therapy</i> , <b>2006</b> , 4, 875-85	5.5	17
28	Partial protective effect of CCR5-Delta 32 heterozygosity in a cohort of heterosexual Italian HIV-1 exposed uninfected individuals. <i>AIDS Research and Therapy</i> , <b>2006</b> , 3, 22	3	24
27	ESBL-producing multidrug-resistant Providencia stuartii infections in a university hospital. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2004</b> , 53, 277-82	5.1	50
26	Older age does not influence CD4 cell recovery in HIV-1 infected patients receiving highly active antiretroviral therapy. <i>BMC Infectious Diseases</i> , <b>2004</b> , 4, 46	4	55
25	Liver fibrosis stage predicts early treatment outcomes with peginterferon plus ribavirin in HIV/hepatitis C virus co-infected patients. <i>Aids</i> , <b>2004</b> , 18, 1602-4	3.5	2
24	Older HIV-positive patients in the era of highly active antiretroviral therapy: changing of a scenario. <i>Aids</i> , <b>2003</b> , 17, 128-31	3.5	48
23	Increased soluble markers of endothelial dysfunction in HIV-positive patients under highly active antiretroviral therapy. <i>Aids</i> , <b>2003</b> , 17, 765-8	3.5	44
22	Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: analysis of trends in prevalence and epidemiology. <i>Emerging Infectious Diseases</i> , <b>2002</b> , 8, 220-1	10.2	69

21	Antiretroviral therapy with protease inhibitors has an early, immune reconstitution-independent beneficial effect on Candida virulence and oral candidiasis in human immunodeficiency virus-infected subjects. <i>Journal of Infectious Diseases</i> , <b>2002</b> , 185, 188-95	7	68
20	Azole susceptibility patterns and genetic relationship among oral Candida strains isolated in the era of highly active antiretroviral therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2002</b> , 31, 38-44	3.1	15
19	Risk factors and predictors of mortality of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia in HIV-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2002</b> , 50, 375-82	5.1	55
18	Glycopeptide resistance among coagulase-negative staphylococci that cause bacteremia: epidemiological and clinical findings from a case-control study. <i>Clinical Infectious Diseases</i> , <b>2001</b> , 33, 167	28-35	42
17	HIV-Associated Bacteremia: How It Has Changed in the Highly Active Antiretroviral Therapy (HAART) Era. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2000</b> , 23, 145-151	3.1	15
16	HIV-associated bacteremia: how it has changed in the highly active antiretroviral therapy (HAART) era. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2000</b> , 23, 145-51	3.1	47
15	Highly active antiretroviral therapy decreases the incidence of visceral leishmaniasis in HIV-infected individuals. <i>Aids</i> , <b>2000</b> , 14, 2948-9	3.5	15
14	Role of protease inhibitors in preventing recurrent oral candidosis in patients with HIV infection: a prospective case-control study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>1999</b> , 21, 20-5	3.1	110
13	In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors. <i>Journal of Infectious Diseases</i> , <b>1999</b> , 180, 448-53	7	179
12	HIV-associated bacterial pneumonia in the era of highly active antiretroviral therapy. <i>Journal of Acquired Immune Deficiency Syndromes</i> , <b>1999</b> , 20, 208-9		15
11	Highly active antiretroviral therapy decreases the incidence of bacteremia in human immunodeficiency virus-infected individuals. <i>Clinical Infectious Diseases</i> , <b>1998</b> , 27, 901-2	11.6	17
10	Nosocomial bloodstream infections in HIV-infected patients: attributable mortality and extension of hospital stay. <i>Journal of Acquired Immune Deficiency Syndromes</i> , <b>1998</b> , 19, 490-7		25
9	Gastric cryptosporidiosis complicating HIV infection: case report and review of the literature. <i>European Journal of Gastroenterology and Hepatology</i> , <b>1997</b> , 9, 307-10	2.2	21
8	Osteoarticular bacterial infections are rare in HIV-infected patients. 14 cases found among 4,023 HIV-infected patients. <i>Acta Orthopaedica</i> , <b>1997</b> , 68, 554-8		32
7	Age as a prognostic factor in AIDS. <i>Lancet, The</i> , <b>1996</b> , 348, 623-4	40	9
6	Analysis of the risk factors associated with the emergence of azole resistant oral candidosis in the course of HIV infection. <i>Journal of Antimicrobial Chemotherapy</i> , <b>1996</b> , 38, 691-9	5.1	45
5	P-170 glycoprotein (P-170) is involved in the impairment of natural killer cell-mediated cytotoxicity in HIV+ patients. <i>Immunology Letters</i> , <b>1995</b> , 47, 223-6	4.1	6
4	Primary central nervous system lymphoma and brain biopsy in AIDS. <i>Lancet, The</i> , <b>1993</b> , 341, 1411-2	40	15

#### LIST OF PUBLICATIONS

3	Synthetic peptides corresponding to sequences in HIV envelope gp41 and gp120 enhance in vitro production of interleukin-1 and tumor necrosis factor but depress production of interferon-alpha, interferon-gamma and interleukin-2. <i>Viral Immunology</i> , <b>1991</b> , 4, 33-42	1.7	35
2	A national voice for information about HIV infections: the Italian state AIDS hot-line. <i>Public Health</i> , <b>1989</b> , 103, 447-54	4	
1	Inhibition of normal human natural killer cell activity by human immunodeficiency virus synthetic transmembrane peptides. <i>Cellular Immunology</i> , <b>1988</b> , 115, 57-65	4.4	43